Avoro Capital Advisors LLC 的 Form 4 申報
Scribe Therapeutics, Inc.SCTX,2026/7/28 申報
- 申報編號
- 0000902664-26-003270
- 申報時間
- 2026/7/28 21:30 ET
- 交易日
- 2026/7/24-7/28
- 申報延遲
- 4 天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 3 筆非衍生性交易。公開市場買進合計 $3,626 萬。交易後 4 天申報。
申報人
一份 Form 4 可以有好幾位申報人,例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Avoro Capital Advisors LLCCIK 0001633313 | 董事、持股 10% 以上大股東、其他:See Remarks |
| Aghazadeh BehzadCIK 0001701815 | 董事、持股 10% 以上大股東、其他:See Remarks |
| Avoro Ventures LLCCIK 0001879253 | 董事、其他:See Remarks |
非衍生性證券(表 I)
普通股等股票的取得與處分,每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/7/24 | Common Stock, par value $0.0001 per share | P買進取得 | +2,333,333 | $15.00F1 | +$34,999,995 | 3,030,983 | 間接 | |
| 2026/7/24 | Common Stock, par value $0.0001 per share | P買進取得 | +50,000 | $22.31F2 | +$1,115,500 | 3,080,983 | 間接 | |
| 2026/7/28 | Common Stock, par value $0.0001 per share | P買進取得 | +7,905 | $18.25F2 | +$144,266.25 | 3,088,888 | 間接 |
附註與備註
本站收錄交易價格引用的附註、修正申報(Form 4/A)的全部附註,以及申報的備註。其他附註,例如間接持有的方式、交易計畫的細節,請看 SEC EDGAR 上的原文。
- F1
The shares reported on this line were purchased from underwriters in the Issuer's initial public offering (the "IPO") at the initial public offering price of $15.00 per share. Of such shares, 2,066,666 shares were purchased on behalf of Avoro Life Sciences Fund LLC ("Avoro Life Sciences") and 266,667 shares were purchased on behalf of Avoro Ventures Fund L.P. ("Avoro Ventures Fund" and, together with Avoro Life Sciences, the "Funds").
表 I 有 1 筆交易的價格引用這則附註。
- F2
The shares reported on these lines were purchased on behalf of Avoro Life Sciences in open market transactions on the dates provided in Column 2.
表 I 有 2 筆交易的價格引用這則附註。
備註
Avoro Capital Advisors and Avoro Ventures may be deemed directors by deputization of the Issuer by virtue of the fact that Dr. Aghazadeh currently serves on the board of directors of the Issuer.